InnovAge (NASDAQ:INNV) Stock Moved Up to “Strong-Buy” by Zacks Research

InnovAge (NASDAQ:INNV – Get Free Report) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday, Zacks reports.

Other equities analysts also recently issued research reports about the company. Weiss Ratings upgraded InnovAge from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. Wall Street Zen upgraded InnovAge from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Finally, KeyCorp boosted their price objective on InnovAge from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.50.

Check Out Our Latest Analysis on InnovAge

InnovAge Trading Down 1.7%

Shares of InnovAge stock opened at $9.42 on Monday. The firm has a 50-day simple moving average of $9.46 and a two-hundred day simple moving average of $9.25. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.16 and a current ratio of 1.16. InnovAge has a fifty-two week low of $4.70 and a fifty-two week high of $12.64. The company has a market cap of $1.29 billion, a P/E ratio of 159.67 and a beta of 0.16.

InnovAge (NASDAQ:INNV – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. InnovAge had a return on equity of 3.63% and a net margin of 0.88%. The firm had revenue of $264.76 million for the quarter, compared to analysts’ expectations of $257.23 million. As a group, equities analysts predict that InnovAge will post 0.44 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Carson Anderson & Stow Welsh sold 1,500,000 shares of InnovAge stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $9.25, for a total value of $13,875,000.00. Following the sale, the insider owned 101,076,555 shares in the company, valued at $934,958,133.75. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Nicole Damato sold 3,402 shares of the business’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $9.51, for a total transaction of $32,353.02. Following the sale, the insider directly owned 301,495 shares of the company’s stock, valued at $2,867,217.45. This represents a 1.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,027,216 shares of company stock worth $120,489,535 over the last 90 days. 1.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On InnovAge

Several institutional investors have recently bought and sold shares of INNV. BlackRock Inc. purchased a new stake in InnovAge during the 2nd quarter worth approximately $17,652,000. Algert Global LLC raised its holdings in shares of InnovAge by 844.1% during the second quarter. Algert Global LLC now owns 630,520 shares of the company’s stock valued at $7,472,000 after acquiring an additional 563,735 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of InnovAge by 207.1% in the third quarter. Goldman Sachs Group Inc. now owns 668,219 shares of the company’s stock valued at $5,880,000 after acquiring an additional 450,610 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of InnovAge in the first quarter valued at approximately $3,349,000. Finally, Marshall Wace LLP acquired a new stake in shares of InnovAge in the third quarter worth approximately $3,589,000. 12.26% of the stock is currently owned by institutional investors and hedge funds.

InnovAge Company Profile

(Get Free Report)

InnovAge, Inc. provides integrated healthcare and social services to older adults through the Program of All-Inclusive Care for the Elderly (PACE). The program serves people who qualify for nursing-home-level care but can continue living in their communities with coordinated support. InnovAge’s services include primary and specialty care coordination, nursing, rehabilitation, social services, prescription medications, transportation, in-home assistance and adult day health services. Care is coordinated by interdisciplinary teams and delivered through a combination of community-based centers and support at home.

See Also

Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.